RhinAer®, the comprehensive, office-friendly solution for chronic rhinitis, was recently featured in specialty clinical news outlet, Healio. The article highlighted RhinAer’s two-year clinical trial results in which significant, long-term symptom improvement and enhanced patient quality of life were achieved following a single, non-invasive treatment.
“I think one of the most important findings of the study was that RhinAer can be used in patients with both allergic and non-allergic rhinitis,” shared Dr. Dale Ehmer Jr., MD, FACS, an investigator in the study. “Additionally, we found sustained positive results in multiple quality-of-life measures with other common symptoms such as post-nasal drip and chronic cough also showing continued improvement.”
The study was an extension of a prospective, multi-center, single-arm trial designed to collect long-term outcomes for a series of patients who had undergone a single treatment on the posterior nasal nerve with RhinAer 24 months prior. The positive results reinforce the long-term efficacy and safety of RhinAer for chronic rhinitis patients.
“It was important for us to do this study to ensure the results were durable. We were pleasantly surprised to confirm that not only do the results last, but they continue to improve through the 2-year mark,” Ehmer said. “Also, the wide swath of symptoms that showed sustained, significant improvement gives ENT physicians the ability to discuss this therapy with a multitude of patients. Patients that suffer from post-nasal drip and cough can be particularly challenging to treat, and we showed that RhinAer improved those symptoms as well,” he continued.
Read the full article here.
Aerin Medical may provide links to third-party sites. The opinions and comments expressed on these third-party sites are their own. Aerin Medical does not claim any accuracy of third-party reporting.
